Napsin A is a specific marker for ovarian clear cell adenocarcinoma
Napsin A is a specific marker for ovarian clear cell adenocarcinoma
复制标题
DOI：
10.1038/modpathol.2014.61
复制
发表时间：
2015-01-01
期刊：
影响因子：
7.5
通讯作者：
Takahashi, Satoru
中科院分区：
文献类型：
--
作者：
Yamashita, Yoriko;Nagasaka, Tetsuro;Takahashi, Satoru
卵巢透明细胞腺癌由于其高化疗耐药性，在卵巢癌亚型中预后相对较差。透明细胞腺癌与其他卵巢表面上皮性肿瘤的鉴别诊断对其治疗至关重要。Napsin A是已知的肺腺癌的诊断标志物，并且报道了Napsin A在甲状腺癌和肾癌的一定部分中的表达。然而，napsin A在卵巢表面上皮性肿瘤中的表达以前没有被研究过。在这项研究中，免疫组化分析显示，在86例卵巢透明细胞腺癌患者中的71例（83%）和所有13例卵巢透明细胞腺纤维瘤患者中，napsin A染色阳性是明显的。在30例卵巢浆液性腺癌、11例卵巢浆液性腺瘤或交界性肿瘤、19例卵巢类腺癌、22例卵巢粘液性腺瘤或交界性肿瘤、10例卵巢粘液性腺癌、3例卵巢卵黄囊肿瘤中均未观察到表达。此外，在卵巢的正常表面上皮、输卵管上皮、鳞状上皮、子宫颈内上皮或子宫内膜中未观察到napsin A的表达。因此，我们建议napsin A是另一个敏感和特异性的标志物，用于区分卵巢透明细胞肿瘤（特别是腺癌）从其他卵巢肿瘤。
Ovarian clear cell adenocarcinoma has a relatively poor prognosis among the ovarian cancer subtypes because of its high chemoresistance. Differential diagnosis of clear cell adenocarcinoma from other ovarian surface epithelial tumors is important for its treatment. Napsin A is a known diagnostic marker for lung adenocarcinoma, and expression of napsin A is reported in a certain portion of thyroid and renal carcinomas. However, napsin A expression in ovarian surface epithelial tumors has not previously been examined. In this study, immunohistochemical analysis revealed that in 71 of 86 ovarian clear cell adenocarcinoma patients (83%) and all of the 13 patients with ovarian clear cell adenofibroma, positive napsin A staining was evident. No expression was observed in 30 serous adenocarcinomas, 11 serous adenomas or borderline tumors, 19 endometrioid adenocarcinomas, 22 mucinous adenomas or borderline tumors, 10 mucinous adenocarcinomas, or 3 yolk sac tumors of the ovary. Furthermore, expression of napsin A was not observed in the normal surface epithelium of the ovary, epithelia of the fallopian tubes, squamous epithelium, endocervical epithelium, or the endometrium of the uterus. Therefore, we propose that napsin A is another sensitive and specific marker for distinguishing ovarian clear cell tumors (especially adenocarcinomas) from other ovarian tumors.